| Host |
Monospecific Mouse |
| Klon |
ZM183 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lymph node. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human BL-CAM/CD22 protein fragment (around aa52-178) |
| Lokalisation |
Cytoplasm |
CD22
|
Zeta Corporation |
ZM183 |
0.5 ml |
Concentrate |
CE/IVD |
Z2496MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM183 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lymph node. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human BL-CAM/CD22 protein fragment (around aa52-178) |
| Lokalisation |
Cytoplasm |
CD22
|
Zeta Corporation |
ZM183 |
0.1 ml |
Concentrate |
CE/IVD |
Z2496MT |
-
|
| Host |
Mouse |
| Klon |
1B12 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:10 - 1:20 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
CD23
|
Diagnostic Biosystems |
1B12 |
1 ml |
Concentrate |
CE/IVD |
MOB294 |
-
|
| Host |
Mouse |
| Klon |
1B12 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:10 - 1:20 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
CD23
|
Diagnostic Biosystems |
1B12 |
0.1 ml |
Concentrate |
CE/IVD |
MOB294-01 |
-
|
| Host |
Mouse |
| Klon |
1B12 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:10 - 1:20 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
CD23
|
Diagnostic Biosystems |
1B12 |
0.5 ml |
Concentrate |
CE/IVD |
MOB294-05 |
-
|
| Host |
Mouse |
| Klon |
1B12 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
CD23
|
Diagnostic Biosystems |
1B12 |
6 ml |
Ready-to-use |
CE/IVD |
PDM143 |
-
|
| Host |
Rabbit |
| Klon |
SP23 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell Membrane |
CD23
|
Diagnostic Biosystems |
SP23 |
1 ml |
Concentrate |
CE/IVD |
RMAB013 |
-
|
| Host |
Rabbit |
| Klon |
SP23 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell Membrane |
CD23
|
Diagnostic Biosystems |
SP23 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB013-01 |
-
|
| Host |
Rabbit |
| Klon |
SP23 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell Membrane |
CD23
|
Diagnostic Biosystems |
SP23 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB013-05 |
-
|
| Host |
Rabbit |
| Klon |
SP23 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell Membrane |
CD23
|
Diagnostic Biosystems |
SP23 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD013 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM209 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil. |
| Verdünnung |
1:50 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment (around aa 48-321) of human FCER2/CD23 protein |
| Lokalisation |
Cell membrane |
CD23
|
Zeta Corporation |
ZM209 |
1 ml |
Concentrate |
CE/IVD |
Z2545ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM209 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment (around aa 48-321) of human FCER2/CD23 protein |
| Lokalisation |
Cell membrane |
CD23
|
Zeta Corporation |
ZM209 |
7 ml |
Ready-to-use |
CE/IVD |
Z2545MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM209 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil. |
| Verdünnung |
1:50 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment (around aa 48-321) of human FCER2/CD23 protein |
| Lokalisation |
Cell membrane |
CD23
|
Zeta Corporation |
ZM209 |
0.5 ml |
Concentrate |
CE/IVD |
Z2545MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM209 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil. |
| Verdünnung |
1:50 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment (around aa 48-321) of human FCER2/CD23 protein |
| Lokalisation |
Cell membrane |
CD23
|
Zeta Corporation |
ZM209 |
0.1 ml |
Concentrate |
CE/IVD |
Z2545MT |
-
|
| Host |
Mouse |
| Klon |
SN3 |
| Format |
Purified |
| Methode |
F, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Glycoprotein purified from human NALM-1 cell line |
CD24
|
Zytomed Systems GmbH |
SN3 |
200 µg |
Purified |
RUO |
603-0677 |
-
|
| Host |
Mouse |
| Klon |
SN3 |
| Format |
Purified |
| Methode |
F, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Glycoprotein purified from human NALM-1 cell line |
CD24
|
Zytomed Systems GmbH |
SN3 |
100 µg |
Purified |
RUO |
603-0678 |
-
|
| Host |
Rabbit |
| Klon |
SP176 |
| Format |
Concentrate |
| Methode |
P, WB |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the C-terminus of human CD25 protein |
| Lokalisation |
Cell Membrane |
CD25
|
Zytomed Systems GmbH |
SP176 |
0.1 ml |
Concentrate |
RUO |
503-4760 |
-
|
| Host |
Rabbit |
| Klon |
SP176 |
| Format |
Concentrate |
| Methode |
P, WB |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the C-terminus of human CD25 protein |
| Lokalisation |
Cell Membrane |
CD25
|
Zytomed Systems GmbH |
SP176 |
0.5 ml |
Concentrate |
RUO |
503-4762 |
-
|
| Host |
Rabbit |
| Klon |
SP176 |
| Format |
Concentrate |
| Methode |
P, WB |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the C-terminus of human CD25 protein |
| Lokalisation |
Cell Membrane |
CD25
|
Zytomed Systems GmbH |
SP176 |
1 ml |
Concentrate |
RUO |
503-4764 |
-
|
| Host |
Mouse |
| Klon |
ZM466 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon, neurofibroma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b |
| Verdünnung |
Recombinant protein corresponding to the external domain of human interleukin-2 receptor protein |
| Lokalisation |
Cytoplasmic |
CD25
|
Zeta Corporation |
ZM466 |
0.1 ml |
Concentrate |
RUO |
Z2817MT-R |
-
|
| Host |
Mouse |
| Klon |
M-A261 |
| Format |
Purified |
| Methode |
F, IP, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human T cell leukemia cells (T-CLL) |
CD26 (Dipeptidyl Peptidase IV)
|
Zytomed Systems GmbH |
M-A261 |
100 µg |
Purified |
RUO |
603-0710 |
-
|
| Host |
Mouse |
| Klon |
4B7R |
| Format |
Purified |
| Methode |
P, IP, FL |
| Vorbehandlung |
(Trypsin) |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Occular melanoma cell line V+B2 |
CD29 (Integrin beta 1)
|
Zytomed Systems GmbH |
4B7R |
200 µg |
Purified |
RUO |
603-0748 |
-
|
| Host |
Mouse |
| Klon |
4B7R |
| Format |
Purified |
| Methode |
P, IP, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Occular melanoma cell line V+B2 |
CD29 (Integrin beta 1)
|
Zytomed Systems GmbH |
4B7R |
100 µg |
Purified |
RUO |
603-0749 |
-
|
| Host |
Mouse |
| Klon |
Ber-H2 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hodgkin lymphoma or anaplastic large cell lymphoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Co cell line established from a patient with Hodgkin's disease of T-cell lineage |
| Lokalisation |
Cell membrane and Cytoplasm |
CD30
|
Zeta Corporation |
Ber-H2 |
1.0 ml |
Concentrate |
CE/IVD |
Z2101ML |
-
|
| Host |
Mouse |
| Klon |
Ber-H2 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hodgkin lymphoma or anaplastic large cell lymphoma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Co cell line established from a patient with Hodgkin's disease of T-cell lineage |
| Lokalisation |
Cell membrane and Cytoplasm |
CD30
|
Zeta Corporation |
Ber-H2 |
7 ml |
Ready-to-use |
CE/IVD |
Z2101MP |
-
|
| Host |
Mouse |
| Klon |
Ber-H2 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hodgkin lymphoma or anaplastic large cell lymphoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Co cell line established from a patient with Hodgkin's disease of T-cell lineage |
| Lokalisation |
Cell membrane and Cytoplasm |
CD30
|
Zeta Corporation |
Ber-H2 |
0.5 ml |
Concentrate |
CE/IVD |
Z2101MS |
-
|
| Host |
Mouse |
| Klon |
Ber-H2 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hodgkin lymphoma or anaplastic large cell lymphoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Co cell line established from a patient with Hodgkin's disease of T-cell lineage |
| Lokalisation |
Cell membrane and Cytoplasm |
CD30
|
Zeta Corporation |
Ber-H2 |
0.1 ml |
Concentrate |
CE/IVD |
Z2101MT |
-
|
| Host |
Rabbit |
| Klon |
ZR248 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hodgkin lymphoma or anaplastic large cell lymphoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human full-length TNFRSF8 protein (CD30) |
| Lokalisation |
Cell membrane and Cytoplasm |
CD30
|
Zeta Corporation |
ZR248 |
1 ml |
Concentrate |
CE/IVD |
Z2489RL |
-
|
| Host |
Rabbit |
| Klon |
ZR248 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hodgkin lymphoma or anaplastic large cell lymphoma |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human full-length TNFRSF8 protein (CD30) |
| Lokalisation |
Cell membrane and Cytoplasm |
CD30
|
Zeta Corporation |
ZR248 |
7 ml |
Ready-to-use |
CE/IVD |
Z2489RP |
-
|
| Host |
Rabbit |
| Klon |
ZR248 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hodgkin lymphoma or anaplastic large cell lymphoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human full-length TNFRSF8 protein (CD30) |
| Lokalisation |
Cell membrane and Cytoplasm |
CD30
|
Zeta Corporation |
ZR248 |
0.5 ml |
Concentrate |
CE/IVD |
Z2489RS |
-
|
| Host |
Rabbit |
| Klon |
ZR248 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hodgkin lymphoma or anaplastic large cell lymphoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human full-length TNFRSF8 protein (CD30) |
| Lokalisation |
Cell membrane and Cytoplasm |
CD30
|
Zeta Corporation |
ZR248 |
0.1 ml |
Concentrate |
CE/IVD |
Z2489RT |
-
|
| Host |
Mouse |
| Klon |
JC70A |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Placenta. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Preparation of a spleen from a patient with hairy cell leukemia |
| Lokalisation |
Cell membrane |
CD31
|
Zeta Corporation |
JC70A |
1.0 ml |
Concentrate |
CE/IVD |
Z2136ML |
-
|
| Host |
Mouse |
| Klon |
JC70A |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Placenta. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Preparation of a spleen from a patient with hairy cell leukemia |
| Lokalisation |
Cell membrane |
CD31
|
Zeta Corporation |
JC70A |
7 ml |
Ready-to-use |
CE/IVD |
Z2136MP |
-
|
| Host |
Mouse |
| Klon |
JC70A |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Placenta. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Preparation of a spleen from a patient with hairy cell leukemia |
| Lokalisation |
Cell membrane |
CD31
|
Zeta Corporation |
JC70A |
0.5 ml |
Concentrate |
CE/IVD |
Z2136MS |
-
|
| Host |
Mouse |
| Klon |
JC70A |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Placenta. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Preparation of a spleen from a patient with hairy cell leukemia |
| Lokalisation |
Cell membrane |
CD31
|
Zeta Corporation |
JC70A |
0.1 ml |
Concentrate |
CE/IVD |
Z2136MT |
-
|
| Host |
Rabbit |
| Klon |
ZR274 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Placenta |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa 625-738) of human CD31 protein (exact sequence is proprietary) |
| Lokalisation |
Cell surface and cytoplasm |
CD31
|
Zeta Corporation |
ZR274 |
1 ml |
Concentrate |
CE/IVD |
Z2725RL |
-
|
| Host |
Rabbit |
| Klon |
ZR274 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Placenta |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa 625-738) of human CD31 protein (exact sequence is proprietary) |
| Lokalisation |
Cell surface and cytoplasm |
CD31
|
Zeta Corporation |
ZR274 |
7 ml |
Concentrate |
CE/IVD |
Z2725RP |
-
|
| Host |
Rabbit |
| Klon |
ZR274 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Placenta |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa 625-738) of human CD31 protein (exact sequence is proprietary) |
| Lokalisation |
Cell surface and cytoplasm |
CD31
|
Zeta Corporation |
ZR274 |
0.5 ml |
Concentrate |
CE/IVD |
Z2725RS |
-
|
| Host |
Rabbit |
| Klon |
ZR274 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Placenta |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa 625-738) of human CD31 protein (exact sequence is proprietary) |
| Lokalisation |
Cell surface and cytoplasm |
CD31
|
Zeta Corporation |
ZR274 |
0.1 ml |
Concentrate |
CE/IVD |
Z2725RT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to C-terminus of mouse CD31 protein. |
| Lokalisation |
Cell Membrane |
CD31 (PECAM-1)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
503-11114 |
-
|
| Host |
Mouse |
| Klon |
JC/70A |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Pepsin |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
CD31 (PECAM-1)
|
Diagnostic Biosystems |
JC/70A |
1 ml |
Concentrate |
CE/IVD |
MOB034 |
-
|
| Host |
Mouse |
| Klon |
JC/70A |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Pepsin |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
CD31 (PECAM-1)
|
Diagnostic Biosystems |
JC/70A |
0.1 ml |
Concentrate |
CE/IVD |
MOB034-01 |
-
|
| Host |
Mouse |
| Klon |
JC/70A |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Pepsin |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
CD31 (PECAM-1)
|
Diagnostic Biosystems |
JC/70A |
0.5 ml |
Concentrate |
CE/IVD |
MOB034-05 |
-
|
| Host |
Mouse |
| Klon |
JC/70A |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Pepsin |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
CD31 (PECAM-1)
|
Diagnostic Biosystems |
JC/70A |
6 ml |
Ready-to-use |
CE/IVD |
PDM020 |
-
|
| Host |
Mouse |
| Klon |
CO.3E1D4 |
| Format |
Purified |
| Methode |
FL |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Sheep leucocytes |
CD31 (PECAM-1) - FITC
|
Zytomed Systems GmbH |
CO.3E1D4 |
100 µg |
Purified |
RUO |
603-0798C |
-
|
| Host |
Mouse |
| Klon |
PWS44 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Myeloid leukemia |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG2b |
| Lokalisation |
Cytoplasm and Cell Membrane |
CD33
|
Biocare Medical |
PWS44 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3116A |
-
|
| Host |
Mouse |
| Klon |
PWS44 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Myeloid leukemia |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG2b |
| Lokalisation |
Cytoplasm and Cell Membrane |
CD33
|
Biocare Medical |
PWS44 |
1 ml |
Concentrate |
CE/IVD |
ACI3116C |
-
|
| Host |
Mouse |
| Klon |
PWS44 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Myeloid leukemia |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2b |
| Lokalisation |
Cytoplasm and Cell Membrane |
CD33
|
Biocare Medical |
PWS44 |
6 ml |
Ready-to-use |
CE/IVD |
API3116AA |
-
|
| Host |
Mouse |
| Klon |
QBEnd/10 |
| Format |
ready-to-use |
| Methode |
IHC, FFPE |
| Vorbehandlung |
Citrate o EDTA |
| Positivkontrolle |
Tonsil, skin or angiosarcoma |
| Verdünnung |
--- |
| Isotyp |
IgG1 |
| Verdünnung |
CD34 |
| Lokalisation |
Cell surface and cytoplasmic |
CD34
|
Biocare Medical |
QBEnd/10 |
6 ml |
ready-to-use |
CE/IVD |
AVI084G |
-
|
| Host |
Mouse |
| Klon |
QBend/10 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD34
|
Diagnostic Biosystems |
QBend/10 |
1 ml |
Concentrate |
CE/IVD |
MOB098 |
-
|